Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma

Liu, Yang; Baba, Yoshifumi; Ishimoto, Takatsugu; Tsutsuki, Hiroyasu; Zhang, Tianli; Nomoto, Daichi; Okadome, Kazuo; Yamamura, Kensuke; Harada, Kazuto; Eto, Kojiro; Hiyoshi, Yukiharu; Iwatsuki, Masaaki; Nagai, Yoshinori; Iwagami, Shiro; Miyamoto, Yuji; Yoshida, Naoya; Komohara, Yoshihiro; Ohmuraya, Masaki; Wang, Xiaoming; Ajani, Jaffer A.; Sawa, Tomohiro; Baba, Hideo

doi:10.1038/s41416-020-01198-5

Cited by 77 publications

(55 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of P. gingivalis in ESCC patients has also been correlated with ESCC stage, poor prognosis, and reduced chemotherapy efficacy [ 170 , 171 , 172 ]. Similarly, F. nucleatum DNA was found to be present at higher levels in ESCC cancer tissues than in paired adjacent nontumor tissues as measured by qPCR [ 173 ], and high levels of F. nucleatum in ESCC tumor tissues have been correlated with a poor prognosis and lower chemotherapeutic response [ 174 , 175 ]. These studies suggest that specific bacteria such as P. gingivalis and F. nucleatum may potentially be useful as prognostic markers, but this does not necessarily indicate that these bacteria play prominent roles in the etiology of ESCC.…”

Section: Esophageal Microbiome and Ecmentioning

confidence: 99%

Microbiome and Cancers of the Esophagus: A Review

2021

View full text Add to dashboard Cite

Esophageal cancer (EC) is an aggressive malignant disease ranking amongst the leading causes of cancer deaths in the world. The two main histologic subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), have distinct geographic and temporal patterns and risk factor profiles. Despite decades of research, the factors underlying these geo-temporal patterns are still not fully understood. The human microbiome has recently been implicated in various health conditions and disease, and it is possible that the microbiome may play an important role in the etiology of EC. Although studies of the microbiome and EC are still in their early stages, we review our current understanding of the potential links between ESCC, EAC, and bacterial communities in the oral cavity and esophagus. We also provide a summary of the epidemiology of EC and highlight some key challenges and future directions.

show abstract

Section: Esophageal Microbiome and Ecmentioning

confidence: 99%

Microbiome and Cancers of the Esophagus: A Review

2021

View full text Add to dashboard Cite

show abstract

“…Fang JY from Shanghai Institute of Digestive Diseases pointed out that F. nucleatum can promote resistance to chemotherapeutic drugs in CRC patients by affecting autophagy-regulating miRNAs [ 36 ]. For other cancers, studies have shown that F. nucleatum regulates the expression of endogenous LC3 and ATG7 and the formation of autophagosomes, resulting in chemoresistance to 5-FU, cisplatin (CDDP), and docetaxel [ 115 ].…”

Section: Crosstalk Between Microbiota and Autophagy In Cancer Developmentmentioning

confidence: 99%

Crosstalk between autophagy and microbiota in cancer progression

Wang

et al. 2021

Mol Cancer

View full text Add to dashboard Cite

Autophagy is a highly conserved catabolic process seen in eukaryotes and is essentially a lysosome-dependent protein degradation pathway. The dysregulation of autophagy is often associated with the pathogenesis of numerous types of cancers, and can not only promote the survival of cancer but also trigger the tumor cell death. During cancer development, the microbial community might predispose cells to tumorigenesis by promoting mucosal inflammation, causing systemic disorders, and may also regulate the immune response to cancer. The complex relationship between autophagy and microorganisms can protect the body by activating the immune system. In addition, autophagy and microorganisms can crosstalk with each other in multifaceted ways to influence various physiological and pathological responses involved in cancer progression. Various molecular mechanisms, correlating the microbiota disorders and autophagy activation, control the outcomes of protumor or antitumor responses, which depend on the cancer type, tumor microenvironment and disease stage. In this review, we mainly emphasize the leading role of autophagy during the interaction between pathogenic microorganisms and human cancers and investigate the various molecular mechanisms by which autophagy modulates such complicated biological processes. Moreover, we also highlight the possibility of curing cancers with multiple molecular agents targeting the microbiota/autophagy axis. Finally, we summarize the emerging clinical trials investigating the therapeutic potential of targeting either autophagy or microbiota as anticancer strategies, although the crosstalk between them has not been explored thoroughly.

show abstract

“…A study from 2020 by Liu Y et al assessed the relationship between chemotherapeutic resistance in esophageal squamous cell carcinoma (ESCC) and Fusobacterium nucleatum . Results showed that ESCC patients which had Fusobacterium nucleatum infection presented lesser therapeutic response to chemotherapy, mostly to 5-fluorouracil, cisplatin and docetaxel, due to the modulation of autophagosome formation induced by Fusobacterium nucleatum [ 83 ].…”

Section: The Impact Of Long-term Antibiotherapy On the Intestinal Microbiome In Crc Patientsmentioning

confidence: 99%

The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients

Mihai

Ion

Giurcăneanu

et al. 2021

JCM

View full text Add to dashboard Cite

Colorectal cancer (CRC) is an important public health issue, in terms of incidence and mortality, with approximately 1.8 million new cases reported worldwide in 2018. Advancements in understanding pathophysiological key steps in CRC tumorigenesis have led to the development of new targeted therapies such as those based on epidermal growth factor receptor inhibitors (EGFR inhibitors). The cutaneous adverse reactions induced by EGFR inhibitors, particularly papulopustular rash, often require long-term antibiotic treatment with tetracycline agents (mostly minocycline and doxycycline). However, this raises several issues of concern: possible occurrence of gut dysbiosis in already vulnerable CRC patients, selection of highly antibiotic resistant and/or virulent clones, development of adverse reactions related to tetracyclines, interference of antibiotics with the response to oncologic therapy, with a negative impact on disease prognosis etc. In the context of scarce information regarding these issues and controversial opinions regarding the role of tetracyclines in patients under EGFR inhibitors, our aim was to perform a thorough literature review and discuss the main challenges raised by long-term use of tetracyclines in advanced CRC patients receiving this targeted therapy.

show abstract

Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma

Cited by 77 publications

References 45 publications

Microbiome and Cancers of the Esophagus: A Review

Microbiome and Cancers of the Esophagus: A Review

Crosstalk between autophagy and microbiota in cancer progression

The Impact of Long-Term Antibiotic Therapy of Cutaneous Adverse Reactions to EGFR Inhibitors in Colorectal Cancer Patients

Contact Info

Product

Resources

About